nodes	percent_of_prediction	percent_of_DWPC	metapath
Cevimeline—CYP3A4—bone cancer	0.748	1	CbGaD
Cevimeline—FMO1—Tamoxifen metabolism—CYP3A4—bone cancer	0.00123	0.116	CbGpPWpGaD
Cevimeline—FMO1—Metapathway biotransformation—CYP4V2—bone cancer	0.00114	0.107	CbGpPWpGaD
Cevimeline—CHRM3—Acetylcholine regulates insulin secretion—GNA11—bone cancer	0.000613	0.0576	CbGpPWpGaD
Cevimeline—FMO1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000432	0.0406	CbGpPWpGaD
Cevimeline—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000397	0.0373	CbGpPWpGaD
Cevimeline—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000396	0.0371	CbGpPWpGaD
Cevimeline—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000259	0.0243	CbGpPWpGaD
Cevimeline—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000243	0.0228	CbGpPWpGaD
Cevimeline—Pollakiuria—Epirubicin—bone cancer	0.000239	0.000992	CcSEcCtD
Cevimeline—Eosinophilia—Doxorubicin—bone cancer	0.000237	0.000984	CcSEcCtD
Cevimeline—Photosensitivity reaction—Epirubicin—bone cancer	0.000236	0.00098	CcSEcCtD
Cevimeline—Feeling abnormal—Cisplatin—bone cancer	0.000236	0.00098	CcSEcCtD
Cevimeline—Weight increased—Epirubicin—bone cancer	0.000236	0.000978	CcSEcCtD
Cevimeline—Haematuria—Methotrexate—bone cancer	0.000235	0.000976	CcSEcCtD
Cevimeline—Weight decreased—Epirubicin—bone cancer	0.000234	0.000972	CcSEcCtD
Cevimeline—Hyperglycaemia—Epirubicin—bone cancer	0.000234	0.000969	CcSEcCtD
Cevimeline—Angina pectoris—Doxorubicin—bone cancer	0.000233	0.000968	CcSEcCtD
Cevimeline—Epistaxis—Methotrexate—bone cancer	0.000233	0.000965	CcSEcCtD
Cevimeline—Pneumonia—Epirubicin—bone cancer	0.000232	0.000963	CcSEcCtD
Cevimeline—Bronchitis—Doxorubicin—bone cancer	0.00023	0.000956	CcSEcCtD
Cevimeline—Agranulocytosis—Methotrexate—bone cancer	0.00023	0.000955	CcSEcCtD
Cevimeline—FMO1—Biological oxidations—CYP3A4—bone cancer	0.000229	0.0215	CbGpPWpGaD
Cevimeline—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000228	0.0214	CbGpPWpGaD
Cevimeline—Body temperature increased—Cisplatin—bone cancer	0.000227	0.00094	CcSEcCtD
Cevimeline—Neuropathy peripheral—Epirubicin—bone cancer	0.000226	0.000939	CcSEcCtD
Cevimeline—FMO1—Metapathway biotransformation—CYP3A4—bone cancer	0.000226	0.0212	CbGpPWpGaD
Cevimeline—Stomatitis—Epirubicin—bone cancer	0.000225	0.000934	CcSEcCtD
Cevimeline—Urinary tract infection—Epirubicin—bone cancer	0.000224	0.000931	CcSEcCtD
Cevimeline—Conjunctivitis—Epirubicin—bone cancer	0.000224	0.000931	CcSEcCtD
Cevimeline—Dysuria—Doxorubicin—bone cancer	0.000224	0.000929	CcSEcCtD
Cevimeline—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000223	0.000924	CcSEcCtD
Cevimeline—Haemoglobin—Methotrexate—bone cancer	0.000223	0.000923	CcSEcCtD
Cevimeline—Haemorrhage—Methotrexate—bone cancer	0.000221	0.000919	CcSEcCtD
Cevimeline—Pollakiuria—Doxorubicin—bone cancer	0.000221	0.000918	CcSEcCtD
Cevimeline—Haematuria—Epirubicin—bone cancer	0.00022	0.000913	CcSEcCtD
Cevimeline—Pharyngitis—Methotrexate—bone cancer	0.00022	0.000912	CcSEcCtD
Cevimeline—Photosensitivity reaction—Doxorubicin—bone cancer	0.000219	0.000907	CcSEcCtD
Cevimeline—Weight increased—Doxorubicin—bone cancer	0.000218	0.000905	CcSEcCtD
Cevimeline—Epistaxis—Epirubicin—bone cancer	0.000218	0.000903	CcSEcCtD
Cevimeline—Urethral disorder—Methotrexate—bone cancer	0.000217	0.000901	CcSEcCtD
Cevimeline—Weight decreased—Doxorubicin—bone cancer	0.000217	0.000899	CcSEcCtD
Cevimeline—Sinusitis—Epirubicin—bone cancer	0.000217	0.000899	CcSEcCtD
Cevimeline—Hyperglycaemia—Doxorubicin—bone cancer	0.000216	0.000897	CcSEcCtD
Cevimeline—Agranulocytosis—Epirubicin—bone cancer	0.000215	0.000894	CcSEcCtD
Cevimeline—Pneumonia—Doxorubicin—bone cancer	0.000215	0.000891	CcSEcCtD
Cevimeline—Visual impairment—Methotrexate—bone cancer	0.000213	0.000885	CcSEcCtD
Cevimeline—Hypersensitivity—Cisplatin—bone cancer	0.000211	0.000876	CcSEcCtD
Cevimeline—Neuropathy peripheral—Doxorubicin—bone cancer	0.000209	0.000869	CcSEcCtD
Cevimeline—Haemoglobin—Epirubicin—bone cancer	0.000208	0.000864	CcSEcCtD
Cevimeline—Stomatitis—Doxorubicin—bone cancer	0.000208	0.000864	CcSEcCtD
Cevimeline—Rhinitis—Epirubicin—bone cancer	0.000208	0.000862	CcSEcCtD
Cevimeline—Urinary tract infection—Doxorubicin—bone cancer	0.000208	0.000861	CcSEcCtD
Cevimeline—Conjunctivitis—Doxorubicin—bone cancer	0.000208	0.000861	CcSEcCtD
Cevimeline—Haemorrhage—Epirubicin—bone cancer	0.000207	0.00086	CcSEcCtD
Cevimeline—Eye disorder—Methotrexate—bone cancer	0.000207	0.000859	CcSEcCtD
Cevimeline—Tinnitus—Methotrexate—bone cancer	0.000207	0.000857	CcSEcCtD
Cevimeline—Hypoaesthesia—Epirubicin—bone cancer	0.000206	0.000855	CcSEcCtD
Cevimeline—Asthenia—Cisplatin—bone cancer	0.000206	0.000853	CcSEcCtD
Cevimeline—Pharyngitis—Epirubicin—bone cancer	0.000206	0.000853	CcSEcCtD
Cevimeline—Cardiac disorder—Methotrexate—bone cancer	0.000206	0.000853	CcSEcCtD
Cevimeline—Oedema peripheral—Epirubicin—bone cancer	0.000204	0.000847	CcSEcCtD
Cevimeline—Haematuria—Doxorubicin—bone cancer	0.000204	0.000845	CcSEcCtD
Cevimeline—Urethral disorder—Epirubicin—bone cancer	0.000203	0.000843	CcSEcCtD
Cevimeline—Epistaxis—Doxorubicin—bone cancer	0.000202	0.000836	CcSEcCtD
Cevimeline—Angiopathy—Methotrexate—bone cancer	0.000201	0.000834	CcSEcCtD
Cevimeline—Sinusitis—Doxorubicin—bone cancer	0.0002	0.000831	CcSEcCtD
Cevimeline—Visual impairment—Epirubicin—bone cancer	0.0002	0.000829	CcSEcCtD
Cevimeline—Agranulocytosis—Doxorubicin—bone cancer	0.000199	0.000827	CcSEcCtD
Cevimeline—Chills—Methotrexate—bone cancer	0.000199	0.000824	CcSEcCtD
Cevimeline—FMO1—Biological oxidations—GSTP1—bone cancer	0.000196	0.0184	CbGpPWpGaD
Cevimeline—Diarrhoea—Cisplatin—bone cancer	0.000196	0.000814	CcSEcCtD
Cevimeline—Alopecia—Methotrexate—bone cancer	0.000196	0.000812	CcSEcCtD
Cevimeline—Eye disorder—Epirubicin—bone cancer	0.000194	0.000803	CcSEcCtD
Cevimeline—FMO1—Metapathway biotransformation—GSTP1—bone cancer	0.000194	0.0182	CbGpPWpGaD
Cevimeline—Tinnitus—Epirubicin—bone cancer	0.000193	0.000802	CcSEcCtD
Cevimeline—Malnutrition—Methotrexate—bone cancer	0.000193	0.0008	CcSEcCtD
Cevimeline—Haemoglobin—Doxorubicin—bone cancer	0.000193	0.0008	CcSEcCtD
Cevimeline—Cardiac disorder—Epirubicin—bone cancer	0.000192	0.000798	CcSEcCtD
Cevimeline—Flushing—Epirubicin—bone cancer	0.000192	0.000798	CcSEcCtD
Cevimeline—Rhinitis—Doxorubicin—bone cancer	0.000192	0.000798	CcSEcCtD
Cevimeline—Haemorrhage—Doxorubicin—bone cancer	0.000192	0.000796	CcSEcCtD
Cevimeline—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000191	0.0179	CbGpPWpGaD
Cevimeline—Hypoaesthesia—Doxorubicin—bone cancer	0.000191	0.000792	CcSEcCtD
Cevimeline—Pharyngitis—Doxorubicin—bone cancer	0.00019	0.00079	CcSEcCtD
Cevimeline—Oedema peripheral—Doxorubicin—bone cancer	0.000189	0.000784	CcSEcCtD
Cevimeline—Dysgeusia—Methotrexate—bone cancer	0.000189	0.000783	CcSEcCtD
Cevimeline—Angiopathy—Epirubicin—bone cancer	0.000188	0.00078	CcSEcCtD
Cevimeline—Urethral disorder—Doxorubicin—bone cancer	0.000188	0.00078	CcSEcCtD
Cevimeline—Back pain—Methotrexate—bone cancer	0.000187	0.000774	CcSEcCtD
Cevimeline—Chills—Epirubicin—bone cancer	0.000186	0.000771	CcSEcCtD
Cevimeline—Arrhythmia—Epirubicin—bone cancer	0.000185	0.000768	CcSEcCtD
Cevimeline—Visual impairment—Doxorubicin—bone cancer	0.000185	0.000767	CcSEcCtD
Cevimeline—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000184	0.0172	CbGpPWpGaD
Cevimeline—Alopecia—Epirubicin—bone cancer	0.000183	0.00076	CcSEcCtD
Cevimeline—Vomiting—Cisplatin—bone cancer	0.000182	0.000756	CcSEcCtD
Cevimeline—Rash—Cisplatin—bone cancer	0.000181	0.00075	CcSEcCtD
Cevimeline—Dermatitis—Cisplatin—bone cancer	0.000181	0.000749	CcSEcCtD
Cevimeline—Malnutrition—Epirubicin—bone cancer	0.00018	0.000748	CcSEcCtD
Cevimeline—Eye disorder—Doxorubicin—bone cancer	0.000179	0.000743	CcSEcCtD
Cevimeline—Ill-defined disorder—Methotrexate—bone cancer	0.000179	0.000742	CcSEcCtD
Cevimeline—Tinnitus—Doxorubicin—bone cancer	0.000179	0.000742	CcSEcCtD
Cevimeline—Anaemia—Methotrexate—bone cancer	0.000178	0.000739	CcSEcCtD
Cevimeline—Flushing—Doxorubicin—bone cancer	0.000178	0.000738	CcSEcCtD
Cevimeline—Cardiac disorder—Doxorubicin—bone cancer	0.000178	0.000738	CcSEcCtD
Cevimeline—Flatulence—Epirubicin—bone cancer	0.000178	0.000738	CcSEcCtD
Cevimeline—Dysgeusia—Epirubicin—bone cancer	0.000177	0.000733	CcSEcCtD
Cevimeline—Back pain—Epirubicin—bone cancer	0.000175	0.000724	CcSEcCtD
Cevimeline—Angiopathy—Doxorubicin—bone cancer	0.000174	0.000722	CcSEcCtD
Cevimeline—Malaise—Methotrexate—bone cancer	0.000174	0.000721	CcSEcCtD
Cevimeline—Muscle spasms—Epirubicin—bone cancer	0.000173	0.00072	CcSEcCtD
Cevimeline—Vertigo—Methotrexate—bone cancer	0.000173	0.000719	CcSEcCtD
Cevimeline—Leukopenia—Methotrexate—bone cancer	0.000173	0.000716	CcSEcCtD
Cevimeline—Chills—Doxorubicin—bone cancer	0.000172	0.000714	CcSEcCtD
Cevimeline—Arrhythmia—Doxorubicin—bone cancer	0.000171	0.000711	CcSEcCtD
Cevimeline—Nausea—Cisplatin—bone cancer	0.00017	0.000707	CcSEcCtD
Cevimeline—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.00017	0.016	CbGpPWpGaD
Cevimeline—Alopecia—Doxorubicin—bone cancer	0.000169	0.000703	CcSEcCtD
Cevimeline—Cough—Methotrexate—bone cancer	0.000168	0.000698	CcSEcCtD
Cevimeline—Ill-defined disorder—Epirubicin—bone cancer	0.000167	0.000694	CcSEcCtD
Cevimeline—Convulsion—Methotrexate—bone cancer	0.000167	0.000693	CcSEcCtD
Cevimeline—Malnutrition—Doxorubicin—bone cancer	0.000167	0.000693	CcSEcCtD
Cevimeline—Anaemia—Epirubicin—bone cancer	0.000167	0.000692	CcSEcCtD
Cevimeline—Agitation—Epirubicin—bone cancer	0.000166	0.000688	CcSEcCtD
Cevimeline—CHRM1—Circadian rythm related genes—TNFRSF11A—bone cancer	0.000165	0.0155	CbGpPWpGaD
Cevimeline—Flatulence—Doxorubicin—bone cancer	0.000165	0.000682	CcSEcCtD
Cevimeline—Arthralgia—Methotrexate—bone cancer	0.000164	0.000681	CcSEcCtD
Cevimeline—Chest pain—Methotrexate—bone cancer	0.000164	0.000681	CcSEcCtD
Cevimeline—Myalgia—Methotrexate—bone cancer	0.000164	0.000681	CcSEcCtD
Cevimeline—Dysgeusia—Doxorubicin—bone cancer	0.000163	0.000678	CcSEcCtD
Cevimeline—Malaise—Epirubicin—bone cancer	0.000163	0.000675	CcSEcCtD
Cevimeline—CHRM3—GPCRs, Other—GRM1—bone cancer	0.000163	0.0153	CbGpPWpGaD
Cevimeline—Discomfort—Methotrexate—bone cancer	0.000162	0.000673	CcSEcCtD
Cevimeline—Vertigo—Epirubicin—bone cancer	0.000162	0.000672	CcSEcCtD
Cevimeline—Syncope—Epirubicin—bone cancer	0.000162	0.000671	CcSEcCtD
Cevimeline—Leukopenia—Epirubicin—bone cancer	0.000162	0.00067	CcSEcCtD
Cevimeline—Back pain—Doxorubicin—bone cancer	0.000161	0.00067	CcSEcCtD
Cevimeline—Muscle spasms—Doxorubicin—bone cancer	0.000161	0.000666	CcSEcCtD
Cevimeline—Palpitations—Epirubicin—bone cancer	0.000159	0.000661	CcSEcCtD
Cevimeline—Confusional state—Methotrexate—bone cancer	0.000159	0.000658	CcSEcCtD
Cevimeline—Loss of consciousness—Epirubicin—bone cancer	0.000159	0.000658	CcSEcCtD
Cevimeline—Cough—Epirubicin—bone cancer	0.000157	0.000653	CcSEcCtD
Cevimeline—Convulsion—Epirubicin—bone cancer	0.000156	0.000648	CcSEcCtD
Cevimeline—Infection—Methotrexate—bone cancer	0.000156	0.000648	CcSEcCtD
Cevimeline—Hypertension—Epirubicin—bone cancer	0.000156	0.000646	CcSEcCtD
Cevimeline—Ill-defined disorder—Doxorubicin—bone cancer	0.000155	0.000643	CcSEcCtD
Cevimeline—Nervous system disorder—Methotrexate—bone cancer	0.000154	0.00064	CcSEcCtD
Cevimeline—Anaemia—Doxorubicin—bone cancer	0.000154	0.00064	CcSEcCtD
Cevimeline—Thrombocytopenia—Methotrexate—bone cancer	0.000154	0.000639	CcSEcCtD
Cevimeline—Arthralgia—Epirubicin—bone cancer	0.000154	0.000637	CcSEcCtD
Cevimeline—Chest pain—Epirubicin—bone cancer	0.000154	0.000637	CcSEcCtD
Cevimeline—Myalgia—Epirubicin—bone cancer	0.000154	0.000637	CcSEcCtD
Cevimeline—Agitation—Doxorubicin—bone cancer	0.000153	0.000636	CcSEcCtD
Cevimeline—Anxiety—Epirubicin—bone cancer	0.000153	0.000635	CcSEcCtD
Cevimeline—Skin disorder—Methotrexate—bone cancer	0.000153	0.000634	CcSEcCtD
Cevimeline—Hyperhidrosis—Methotrexate—bone cancer	0.000152	0.000631	CcSEcCtD
Cevimeline—Discomfort—Epirubicin—bone cancer	0.000152	0.00063	CcSEcCtD
Cevimeline—Malaise—Doxorubicin—bone cancer	0.000151	0.000625	CcSEcCtD
Cevimeline—Vertigo—Doxorubicin—bone cancer	0.00015	0.000622	CcSEcCtD
Cevimeline—Anorexia—Methotrexate—bone cancer	0.00015	0.000622	CcSEcCtD
Cevimeline—Syncope—Doxorubicin—bone cancer	0.00015	0.000621	CcSEcCtD
Cevimeline—Leukopenia—Doxorubicin—bone cancer	0.000149	0.00062	CcSEcCtD
Cevimeline—Confusional state—Epirubicin—bone cancer	0.000148	0.000616	CcSEcCtD
Cevimeline—Palpitations—Doxorubicin—bone cancer	0.000148	0.000612	CcSEcCtD
Cevimeline—Oedema—Epirubicin—bone cancer	0.000147	0.000611	CcSEcCtD
Cevimeline—Hypotension—Methotrexate—bone cancer	0.000147	0.00061	CcSEcCtD
Cevimeline—Loss of consciousness—Doxorubicin—bone cancer	0.000147	0.000609	CcSEcCtD
Cevimeline—Infection—Epirubicin—bone cancer	0.000146	0.000607	CcSEcCtD
Cevimeline—Cough—Doxorubicin—bone cancer	0.000146	0.000604	CcSEcCtD
Cevimeline—Shock—Epirubicin—bone cancer	0.000145	0.000601	CcSEcCtD
Cevimeline—Convulsion—Doxorubicin—bone cancer	0.000145	0.0006	CcSEcCtD
Cevimeline—Nervous system disorder—Epirubicin—bone cancer	0.000144	0.000599	CcSEcCtD
Cevimeline—Thrombocytopenia—Epirubicin—bone cancer	0.000144	0.000598	CcSEcCtD
Cevimeline—Hypertension—Doxorubicin—bone cancer	0.000144	0.000598	CcSEcCtD
Cevimeline—Tachycardia—Epirubicin—bone cancer	0.000144	0.000596	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000143	0.000595	CcSEcCtD
Cevimeline—Skin disorder—Epirubicin—bone cancer	0.000143	0.000593	CcSEcCtD
Cevimeline—Hyperhidrosis—Epirubicin—bone cancer	0.000142	0.000591	CcSEcCtD
Cevimeline—Insomnia—Methotrexate—bone cancer	0.000142	0.00059	CcSEcCtD
Cevimeline—Myalgia—Doxorubicin—bone cancer	0.000142	0.00059	CcSEcCtD
Cevimeline—Arthralgia—Doxorubicin—bone cancer	0.000142	0.00059	CcSEcCtD
Cevimeline—Chest pain—Doxorubicin—bone cancer	0.000142	0.00059	CcSEcCtD
Cevimeline—Anxiety—Doxorubicin—bone cancer	0.000142	0.000588	CcSEcCtD
Cevimeline—Paraesthesia—Methotrexate—bone cancer	0.000141	0.000586	CcSEcCtD
Cevimeline—Discomfort—Doxorubicin—bone cancer	0.00014	0.000583	CcSEcCtD
Cevimeline—Anorexia—Epirubicin—bone cancer	0.00014	0.000582	CcSEcCtD
Cevimeline—Dyspnoea—Methotrexate—bone cancer	0.00014	0.000582	CcSEcCtD
Cevimeline—Somnolence—Methotrexate—bone cancer	0.00014	0.00058	CcSEcCtD
Cevimeline—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00014	0.0131	CbGpPWpGaD
Cevimeline—Dyspepsia—Methotrexate—bone cancer	0.000139	0.000575	CcSEcCtD
Cevimeline—Hypotension—Epirubicin—bone cancer	0.000138	0.000571	CcSEcCtD
Cevimeline—FMO1—Metabolism—NDUFA12—bone cancer	0.000138	0.0129	CbGpPWpGaD
Cevimeline—Confusional state—Doxorubicin—bone cancer	0.000137	0.00057	CcSEcCtD
Cevimeline—Decreased appetite—Methotrexate—bone cancer	0.000137	0.000567	CcSEcCtD
Cevimeline—Oedema—Doxorubicin—bone cancer	0.000136	0.000565	CcSEcCtD
Cevimeline—Fatigue—Methotrexate—bone cancer	0.000136	0.000563	CcSEcCtD
Cevimeline—Infection—Doxorubicin—bone cancer	0.000135	0.000561	CcSEcCtD
Cevimeline—Pain—Methotrexate—bone cancer	0.000135	0.000558	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000134	0.000557	CcSEcCtD
Cevimeline—Shock—Doxorubicin—bone cancer	0.000134	0.000556	CcSEcCtD
Cevimeline—Nervous system disorder—Doxorubicin—bone cancer	0.000134	0.000554	CcSEcCtD
Cevimeline—Thrombocytopenia—Doxorubicin—bone cancer	0.000133	0.000553	CcSEcCtD
Cevimeline—Insomnia—Epirubicin—bone cancer	0.000133	0.000552	CcSEcCtD
Cevimeline—Tachycardia—Doxorubicin—bone cancer	0.000133	0.000552	CcSEcCtD
Cevimeline—Skin disorder—Doxorubicin—bone cancer	0.000132	0.000549	CcSEcCtD
Cevimeline—Paraesthesia—Epirubicin—bone cancer	0.000132	0.000548	CcSEcCtD
Cevimeline—Hyperhidrosis—Doxorubicin—bone cancer	0.000132	0.000546	CcSEcCtD
Cevimeline—Dyspnoea—Epirubicin—bone cancer	0.000131	0.000545	CcSEcCtD
Cevimeline—Somnolence—Epirubicin—bone cancer	0.000131	0.000543	CcSEcCtD
Cevimeline—Anorexia—Doxorubicin—bone cancer	0.00013	0.000539	CcSEcCtD
Cevimeline—Feeling abnormal—Methotrexate—bone cancer	0.00013	0.000538	CcSEcCtD
Cevimeline—Dyspepsia—Epirubicin—bone cancer	0.00013	0.000538	CcSEcCtD
Cevimeline—Gastrointestinal pain—Methotrexate—bone cancer	0.000129	0.000534	CcSEcCtD
Cevimeline—Decreased appetite—Epirubicin—bone cancer	0.000128	0.000531	CcSEcCtD
Cevimeline—Hypotension—Doxorubicin—bone cancer	0.000127	0.000528	CcSEcCtD
Cevimeline—Fatigue—Epirubicin—bone cancer	0.000127	0.000527	CcSEcCtD
Cevimeline—CHRM1—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.000127	0.0119	CbGpPWpGaD
Cevimeline—CHRM3—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.000126	0.0119	CbGpPWpGaD
Cevimeline—Pain—Epirubicin—bone cancer	0.000126	0.000522	CcSEcCtD
Cevimeline—Constipation—Epirubicin—bone cancer	0.000126	0.000522	CcSEcCtD
Cevimeline—Urticaria—Methotrexate—bone cancer	0.000125	0.000519	CcSEcCtD
Cevimeline—Body temperature increased—Methotrexate—bone cancer	0.000124	0.000516	CcSEcCtD
Cevimeline—Abdominal pain—Methotrexate—bone cancer	0.000124	0.000516	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000124	0.000515	CcSEcCtD
Cevimeline—Insomnia—Doxorubicin—bone cancer	0.000123	0.000511	CcSEcCtD
Cevimeline—Paraesthesia—Doxorubicin—bone cancer	0.000122	0.000508	CcSEcCtD
Cevimeline—Dyspnoea—Doxorubicin—bone cancer	0.000121	0.000504	CcSEcCtD
Cevimeline—Feeling abnormal—Epirubicin—bone cancer	0.000121	0.000503	CcSEcCtD
Cevimeline—Somnolence—Doxorubicin—bone cancer	0.000121	0.000502	CcSEcCtD
Cevimeline—Gastrointestinal pain—Epirubicin—bone cancer	0.00012	0.000499	CcSEcCtD
Cevimeline—Dyspepsia—Doxorubicin—bone cancer	0.00012	0.000498	CcSEcCtD
Cevimeline—CHRM3—Regulation of insulin secretion—GNA11—bone cancer	0.00012	0.0112	CbGpPWpGaD
Cevimeline—Decreased appetite—Doxorubicin—bone cancer	0.000118	0.000491	CcSEcCtD
Cevimeline—Fatigue—Doxorubicin—bone cancer	0.000117	0.000487	CcSEcCtD
Cevimeline—Urticaria—Epirubicin—bone cancer	0.000117	0.000485	CcSEcCtD
Cevimeline—Constipation—Doxorubicin—bone cancer	0.000117	0.000483	CcSEcCtD
Cevimeline—Pain—Doxorubicin—bone cancer	0.000117	0.000483	CcSEcCtD
Cevimeline—Abdominal pain—Epirubicin—bone cancer	0.000116	0.000483	CcSEcCtD
Cevimeline—Body temperature increased—Epirubicin—bone cancer	0.000116	0.000483	CcSEcCtD
Cevimeline—Hypersensitivity—Methotrexate—bone cancer	0.000116	0.000481	CcSEcCtD
Cevimeline—CHRM3—GPCRs, Other—SMO—bone cancer	0.000115	0.0108	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—NT5C3A—bone cancer	0.000114	0.0107	CbGpPWpGaD
Cevimeline—Asthenia—Methotrexate—bone cancer	0.000113	0.000468	CcSEcCtD
Cevimeline—Feeling abnormal—Doxorubicin—bone cancer	0.000112	0.000466	CcSEcCtD
Cevimeline—Gastrointestinal pain—Doxorubicin—bone cancer	0.000111	0.000462	CcSEcCtD
Cevimeline—Pruritus—Methotrexate—bone cancer	0.000111	0.000462	CcSEcCtD
Cevimeline—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000111	0.0104	CbGpPWpGaD
Cevimeline—Hypersensitivity—Epirubicin—bone cancer	0.000108	0.00045	CcSEcCtD
Cevimeline—Urticaria—Doxorubicin—bone cancer	0.000108	0.000449	CcSEcCtD
Cevimeline—Abdominal pain—Doxorubicin—bone cancer	0.000108	0.000447	CcSEcCtD
Cevimeline—Body temperature increased—Doxorubicin—bone cancer	0.000108	0.000447	CcSEcCtD
Cevimeline—Diarrhoea—Methotrexate—bone cancer	0.000108	0.000447	CcSEcCtD
Cevimeline—Asthenia—Epirubicin—bone cancer	0.000106	0.000438	CcSEcCtD
Cevimeline—Pruritus—Epirubicin—bone cancer	0.000104	0.000432	CcSEcCtD
Cevimeline—Dizziness—Methotrexate—bone cancer	0.000104	0.000432	CcSEcCtD
Cevimeline—Diarrhoea—Epirubicin—bone cancer	0.000101	0.000418	CcSEcCtD
Cevimeline—Hypersensitivity—Doxorubicin—bone cancer	0.0001	0.000416	CcSEcCtD
Cevimeline—Vomiting—Methotrexate—bone cancer	0.0001	0.000415	CcSEcCtD
Cevimeline—Rash—Methotrexate—bone cancer	9.92e-05	0.000412	CcSEcCtD
Cevimeline—Dermatitis—Methotrexate—bone cancer	9.91e-05	0.000411	CcSEcCtD
Cevimeline—Headache—Methotrexate—bone cancer	9.86e-05	0.000409	CcSEcCtD
Cevimeline—Asthenia—Doxorubicin—bone cancer	9.78e-05	0.000406	CcSEcCtD
Cevimeline—Dizziness—Epirubicin—bone cancer	9.74e-05	0.000404	CcSEcCtD
Cevimeline—Pruritus—Doxorubicin—bone cancer	9.64e-05	0.0004	CcSEcCtD
Cevimeline—CHRM3—Integration of energy metabolism—GNA11—bone cancer	9.42e-05	0.00884	CbGpPWpGaD
Cevimeline—Vomiting—Epirubicin—bone cancer	9.36e-05	0.000388	CcSEcCtD
Cevimeline—Nausea—Methotrexate—bone cancer	9.35e-05	0.000388	CcSEcCtD
Cevimeline—Diarrhoea—Doxorubicin—bone cancer	9.32e-05	0.000387	CcSEcCtD
Cevimeline—Rash—Epirubicin—bone cancer	9.29e-05	0.000385	CcSEcCtD
Cevimeline—Dermatitis—Epirubicin—bone cancer	9.28e-05	0.000385	CcSEcCtD
Cevimeline—Headache—Epirubicin—bone cancer	9.23e-05	0.000383	CcSEcCtD
Cevimeline—CHRM1—G alpha (q) signalling events—GRM1—bone cancer	9.17e-05	0.00861	CbGpPWpGaD
Cevimeline—CHRM3—G alpha (q) signalling events—GRM1—bone cancer	9.14e-05	0.00858	CbGpPWpGaD
Cevimeline—Dizziness—Doxorubicin—bone cancer	9.01e-05	0.000374	CcSEcCtD
Cevimeline—Nausea—Epirubicin—bone cancer	8.75e-05	0.000363	CcSEcCtD
Cevimeline—Vomiting—Doxorubicin—bone cancer	8.66e-05	0.000359	CcSEcCtD
Cevimeline—Rash—Doxorubicin—bone cancer	8.59e-05	0.000356	CcSEcCtD
Cevimeline—Dermatitis—Doxorubicin—bone cancer	8.58e-05	0.000356	CcSEcCtD
Cevimeline—Headache—Doxorubicin—bone cancer	8.54e-05	0.000354	CcSEcCtD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	8.2e-05	0.0077	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	8.17e-05	0.00767	CbGpPWpGaD
Cevimeline—Nausea—Doxorubicin—bone cancer	8.09e-05	0.000336	CcSEcCtD
Cevimeline—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	7.93e-05	0.00744	CbGpPWpGaD
Cevimeline—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	7.82e-05	0.00734	CbGpPWpGaD
Cevimeline—CHRM1—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	7.09e-05	0.00665	CbGpPWpGaD
Cevimeline—CHRM3—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	7.06e-05	0.00663	CbGpPWpGaD
Cevimeline—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	6.43e-05	0.00603	CbGpPWpGaD
Cevimeline—CHRM1—G alpha (q) signalling events—GNA11—bone cancer	5.91e-05	0.00555	CbGpPWpGaD
Cevimeline—CHRM3—G alpha (q) signalling events—GNA11—bone cancer	5.89e-05	0.00553	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—GNA11—bone cancer	5.58e-05	0.00524	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—EZH2—bone cancer	5.55e-05	0.00521	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—GRM4—bone cancer	5.33e-05	0.00501	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—GRM4—bone cancer	5.32e-05	0.00499	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	5.28e-05	0.00496	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	5.27e-05	0.00494	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—ENO2—bone cancer	4.99e-05	0.00469	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—DHFR—bone cancer	4.63e-05	0.00435	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—GRM1—bone cancer	4.62e-05	0.00434	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—GRM1—bone cancer	4.61e-05	0.00433	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—GNA11—bone cancer	4.33e-05	0.00406	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—CYP3A4—bone cancer	3.92e-05	0.00368	CbGpPWpGaD
Cevimeline—CHRM1—Regulation of Actin Cytoskeleton—BRAF—bone cancer	3.52e-05	0.00331	CbGpPWpGaD
Cevimeline—CHRM3—Regulation of Actin Cytoskeleton—BRAF—bone cancer	3.51e-05	0.0033	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—NDUFA12—bone cancer	3.42e-05	0.00321	CbGpPWpGaD
Cevimeline—CYP2D6—Biological oxidations—CYP3A4—bone cancer	3.41e-05	0.0032	CbGpPWpGaD
Cevimeline—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	3.37e-05	0.00316	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—GSTP1—bone cancer	3.36e-05	0.00315	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—SMO—bone cancer	3.26e-05	0.00306	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—SMO—bone cancer	3.25e-05	0.00305	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—CDK4—bone cancer	3.13e-05	0.00294	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—RGS1—bone cancer	3.01e-05	0.00283	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—GRM4—bone cancer	3.01e-05	0.00283	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—GRM4—bone cancer	3e-05	0.00282	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—RGS1—bone cancer	3e-05	0.00282	CbGpPWpGaD
Cevimeline—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	2.95e-05	0.00277	CbGpPWpGaD
Cevimeline—CYP2D6—Biological oxidations—GSTP1—bone cancer	2.92e-05	0.00274	CbGpPWpGaD
Cevimeline—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	2.88e-05	0.0027	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—NT5C3A—bone cancer	2.84e-05	0.00266	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—GRM4—bone cancer	2.74e-05	0.00257	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—RGS1—bone cancer	2.74e-05	0.00257	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—RGS1—bone cancer	2.73e-05	0.00256	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—GRM4—bone cancer	2.73e-05	0.00256	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—GRM1—bone cancer	2.61e-05	0.00245	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—GRM1—bone cancer	2.6e-05	0.00245	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—GRM1—bone cancer	2.37e-05	0.00223	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—GRM1—bone cancer	2.37e-05	0.00222	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—NDUFA12—bone cancer	2.05e-05	0.00192	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—JUN—bone cancer	2.02e-05	0.0019	CbGpPWpGaD
Cevimeline—CHRM1—Regulation of Actin Cytoskeleton—EGFR—bone cancer	2.02e-05	0.00189	CbGpPWpGaD
Cevimeline—CHRM3—Regulation of Actin Cytoskeleton—EGFR—bone cancer	2.01e-05	0.00189	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—GSTP1—bone cancer	1.91e-05	0.00179	CbGpPWpGaD
Cevimeline—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	1.88e-05	0.00177	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—PTGS2—bone cancer	1.74e-05	0.00163	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—NT5C3A—bone cancer	1.7e-05	0.00159	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—GNA11—bone cancer	1.68e-05	0.00158	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—GNA11—bone cancer	1.68e-05	0.00158	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—SMO—bone cancer	1.67e-05	0.00157	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—SMO—bone cancer	1.67e-05	0.00156	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—RGS1—bone cancer	1.62e-05	0.00152	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—GRM4—bone cancer	1.62e-05	0.00152	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—GRM4—bone cancer	1.61e-05	0.00151	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—RGS1—bone cancer	1.61e-05	0.00151	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—GNA11—bone cancer	1.53e-05	0.00144	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—IL3—bone cancer	1.53e-05	0.00143	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—GNA11—bone cancer	1.52e-05	0.00143	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—IL3—bone cancer	1.52e-05	0.00143	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	1.5e-05	0.00141	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	1.5e-05	0.00141	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—GRM1—bone cancer	1.4e-05	0.00132	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—GRM1—bone cancer	1.4e-05	0.00131	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—IL3—bone cancer	1.39e-05	0.0013	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—IL3—bone cancer	1.38e-05	0.0013	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—NDUFA12—bone cancer	1.34e-05	0.00126	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—TP53—bone cancer	1.33e-05	0.00125	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ENO2—bone cancer	1.24e-05	0.00117	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—DHFR—bone cancer	1.15e-05	0.00108	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—NT5C3A—bone cancer	1.11e-05	0.00104	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GNA11—bone cancer	1.08e-05	0.00101	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SMO—bone cancer	9.88e-06	0.000927	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SMO—bone cancer	9.84e-06	0.000924	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CYP3A4—bone cancer	9.76e-06	0.000916	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—GNA11—bone cancer	9.03e-06	0.000848	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—GNA11—bone cancer	9e-06	0.000845	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—ATF1—bone cancer	8.4e-06	0.000788	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—ATF1—bone cancer	8.37e-06	0.000786	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GSTP1—bone cancer	8.35e-06	0.000784	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IL3—bone cancer	8.19e-06	0.000769	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IL3—bone cancer	8.16e-06	0.000766	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ENO2—bone cancer	7.43e-06	0.000697	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TGFBR2—bone cancer	7e-06	0.000658	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TGFBR2—bone cancer	6.98e-06	0.000655	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—DHFR—bone cancer	6.89e-06	0.000647	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IGF1R—bone cancer	6.59e-06	0.000619	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IGF1R—bone cancer	6.57e-06	0.000617	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GNA11—bone cancer	6.44e-06	0.000604	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP3A4—bone cancer	5.84e-06	0.000548	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTP1—bone cancer	4.99e-06	0.000469	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ENO2—bone cancer	4.85e-06	0.000456	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—KIT—bone cancer	4.78e-06	0.000449	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—KIT—bone cancer	4.76e-06	0.000447	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—DHFR—bone cancer	4.5e-06	0.000423	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—BRAF—bone cancer	4.49e-06	0.000422	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—BRAF—bone cancer	4.48e-06	0.00042	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—EGFR—bone cancer	4.35e-06	0.000409	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—EGFR—bone cancer	4.34e-06	0.000407	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PTGS2—bone cancer	4.33e-06	0.000406	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GNA11—bone cancer	4.21e-06	0.000395	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MDM2—bone cancer	3.76e-06	0.000353	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MDM2—bone cancer	3.75e-06	0.000352	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—JUN—bone cancer	3.27e-06	0.000307	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTP1—bone cancer	3.26e-06	0.000306	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—JUN—bone cancer	3.26e-06	0.000306	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MMP9—bone cancer	3.18e-06	0.000299	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MMP9—bone cancer	3.17e-06	0.000298	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PTGS2—bone cancer	2.59e-06	0.000243	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—EGFR—bone cancer	2.57e-06	0.000241	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—EGFR—bone cancer	2.56e-06	0.000241	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TP53—bone cancer	2.16e-06	0.000203	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TP53—bone cancer	2.15e-06	0.000202	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PTGS2—bone cancer	1.69e-06	0.000159	CbGpPWpGaD
